In the mid-1990s, Amgen scientists pioneered research that
changed the understanding of bone biology.

Amgen researchers W. Scott Simonet, David Lacey, and William J. Boyle published the first description of osteoprotegerin in a 1997 Cell paper1. Further research led to the identification of the RANK Ligand pathway.

That discovery has been fundamental not only to Amgen's commitment to furthering our understanding of the science of bone biology, but also to the work of many of researchers around the world.

Learn more about the role of the RANK Ligand pathway.
EU Residents Click here »
Canada Residents Click here »

1 Simonet WS, et al. Cell. 1997;89(2):309-319.

This website is intended to be an educational resource only. It is not intended or deemed to be a directive regarding appropriate diagnosis or treatment. The treating physician is solely responsible for making all decisions relating to appropriate patient care, including but not limited to diagnosis, surgery, medications, dose, schedule, and any supportive care.

Amgen Inc. disclaims any liability or damages arising from any errors or use of this information.